|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
| Capitalization1 |
40 077 | 40 385 | 41 049 | 50 990 | 66 029 | 71 927 | - | - |
| Enterprise Value (EV)1 |
39 370 | 38 283 | 35 291 | 50 098 | 56 196 | 63 211 | 59 545 | 57 653 |
| P/E ratio |
36,4x | 17,5x | 20,3x | 15,8x | 8,77x | 18,0x | 17,0x | 16,9x |
| Yield |
- | - | - | - | - | - | - | - |
| Capitalization / Revenue |
6,82x | 6,02x | 5,22x | 6,00x | 4,11x | 6,07x | 5,84x | 5,69x |
| EV / Revenue |
6,70x | 5,70x | 4,49x | 5,90x | 3,50x | 5,34x | 4,84x | 4,56x |
| EV / EBITDA |
14,4x | 12,3x | 10,3x | 11,8x | 5,71x | 10,6x | 9,07x | 8,35x |
| Price to Book |
6,59x | 4,90x | 3,70x | 4,71x | 3,56x | 2,71x | 2,30x | 1,85x |
| Nbr of stocks (in thousands) |
106 598 | 108 125 | 109 323 | 105 544 | 104 556 | 107 746 | - | - |
| Reference price (USD) |
376 | 374 | 375 | 483 | 632 | 668 | 668 | 668 |
| Announcement Date |
02/08/2018 | 02/06/2019 | 02/06/2020 | 02/05/2021 | 02/04/2022 | - | - | - |
1 USD in Million |
|
|
| Income Statement Evolution (Annual data) |
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
| Net sales1 |
5 872 | 6 711 | 7 863 | 8 497 | 16 072 | 11 844 | 12 311 | 12 647 |
| EBITDA1 |
2 732 | 3 110 | 3 420 | 4 245 | 9 835 | 5 944 | 6 566 | 6 903 |
| Operating profit (EBIT)1 |
2 080 | 2 534 | 2 210 | 3 577 | 8 947 | 4 899 | 5 107 | 5 053 |
| Operating Margin |
35,4% | 37,8% | 28,1% | 42,1% | 55,7% | 41,4% | 41,5% | 40,0% |
| Pre-Tax Profit (EBT)1 |
2 079 | 2 554 | 2 429 | 3 810 | 9 326 | 4 968 | 5 117 | 5 100 |
| Net income1 |
1 199 | 2 444 | 2 116 | 3 513 | 8 075 | 4 040 | 4 163 | 4 092 |
| Net margin |
20,4% | 36,4% | 26,9% | 41,3% | 50,2% | 34,1% | 33,8% | 32,4% |
| EPS2 |
10,3 | 21,3 | 18,5 | 30,5 | 72,0 | 37,1 | 39,2 | 39,6 |
| Dividend per Share2 |
- | - | - | - | - | - | - | - |
| Announcement Date |
02/08/2018 | 02/06/2019 | 02/06/2020 | 02/05/2021 | 02/04/2022 | - | - | - |
1 USD in Million 2 USD |
|
|
| Income Statement Evolution (Quarterly data) |
|
|
Fiscal Period: December
|
2019 Q4 |
2020 Q1 |
2020 Q2 |
2020 Q3 |
2020 Q4 |
2021 Q1 |
2021 Q2 |
2021 Q3 |
2021 Q4 |
2022 Q1 |
2022 Q2 |
2022 Q3 |
2022 Q4 |
2023 Q1 |
2023 Q2 |
| Net sales1 |
2 170 | 1 828 | 1 952 | 2 294 | 2 423 | 2 529 | 5 139 | 3 453 | 4 952 | 2 965 | 2 817 | 2 969 | 2 970 | 2 887 | 2 922 |
| EBITDA1 |
989 | 756 | 715 | 1 112 | 1 229 | 1 311 | 3 564 | 2 057 | 2 903 | 1 528 | 1 303 | 1 387 | 1 343 | 1 420 | 1 214 |
| Operating profit (EBIT)1 |
676 | 700 | 656 | 1 053 | 1 167 | 1 113 | 3 347 | 1 847 | 2 640 | 1 287 | 1 222 | 1 250 | 1 276 | 1 443 | 1 353 |
| Operating Margin |
31,1% | 38,3% | 33,6% | 45,9% | 48,2% | 44,0% | 65,1% | 53,5% | 53,3% | 43,4% | 43,4% | 42,1% | 43,0% | 50,0% | 46,3% |
| Pre-Tax Profit (EBT)1 |
890 | 669 | 919 | 998 | 1 225 | 1 253 | 3 753 | 1 817 | 2 503 | 1 061 | 1 241 | 1 326 | 1 359 | 1 470 | 1 384 |
| Net income1 |
792 | 625 | 897 | 842 | 1 149 | 1 115 | 3 099 | 1 632 | 2 229 | 974 | 923 | 968 | 961 | 1 018 | 1 015 |
| Net margin |
36,5% | 34,2% | 46,0% | 36,7% | 47,4% | 44,1% | 60,3% | 47,3% | 45,0% | 32,8% | 32,8% | 32,6% | 32,4% | 35,3% | 34,7% |
| EPS2 |
6,93 | 5,43 | 7,61 | 7,39 | 10,2 | 10,1 | 28,0 | 14,3 | 19,7 | 8,61 | 9,06 | 9,72 | 8,60 | 9,04 | 8,98 |
| Dividend per Share |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date |
02/06/2020 | 05/05/2020 | 08/05/2020 | 11/05/2020 | 02/05/2021 | 05/06/2021 | 08/05/2021 | 11/04/2021 | 02/04/2022 | 05/04/2022 | - | - | - | - | - |
1 USD in Million 2 USD |
|
|
|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
| Net Debt1 |
- | - | - | - | - | - | - | - |
| Net Cash position1 |
706 | 2 101 | 5 757 | 891 | 9 833 | 8 716 | 12 382 | 14 274 |
| Leverage (Debt / EBITDA) |
-0,26x | -0,68x | -1,68x | -0,21x | -1,00x | -1,47x | -1,89x | -2,07x |
| Free Cash Flow1 |
1 034 | 1 812 | 2 000 | 2 004 | 6 529 | 6 558 | 5 243 | 5 465 |
| ROE (Net Profit / Equities) |
22,6% | 32,8% | 28,5% | 33,2% | 54,2% | 23,2% | 20,3% | 17,8% |
| Shareholders' equity1 |
5 297 | 7 451 | 7 427 | 10 595 | 14 897 | 17 448 | 20 496 | 22 940 |
| ROA (Net Profit / Asset) |
15,2% | 23,8% | 15,9% | 22,0% | 37,9% | 16,2% | 15,7% | 13,9% |
| Assets1 |
7 869 | 10 249 | 13 270 | 15 984 | 21 299 | 24 897 | 26 455 | 29 388 |
| Book Value Per Share2 |
57,1 | 76,3 | 102 | 102 | 178 | 247 | 290 | 361 |
| Cash Flow per Share2 |
11,3 | 19,1 | 21,2 | 22,7 | 63,1 | 65,2 | 45,9 | 51,2 |
| Capex1 |
273 | 383 | 430 | 615 | 552 | 607 | 619 | 630 |
| Capex / Sales |
4,64% | 5,71% | 5,46% | 7,23% | 3,43% | 5,13% | 5,03% | 4,98% |
| Announcement Date |
02/08/2018 | 02/06/2019 | 02/06/2020 | 02/05/2021 | 02/04/2022 | - | - | - |
1 USD in Million 2 USD |
|
|
|
|
|
Regeneron's COVID drug sales outside U.S. help revenue beat |
| Capitalization (USD) |
71 927 049 266 |
| Net sales (USD) |
16 071 700 000 |
| Number of employees |
10 492 |
| Sales / Employee (USD) |
1 531 805 |
| Free-Float |
81,0% |
| Free-Float capitalization (USD) |
58 257 397 108 |
| Avg. Exchange 20 sessions (USD) |
453 314 495 |
| Average Daily Capital Traded |
0,63% |
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
|
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
Previous period
